Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-30.22	-28.13	-30.93	-31.64	-20.64	-13.68
Depreciation & Amortization	0.25	0.25	0.22	0.22	0.23	0.15
Asset Writedown & Restructuring Costs	-	-	1.36	0.08	0.08	0.5
Stock-Based Compensation	4.63	4.17	5.54	12.61	2.81	3.27
Other Operating Activities	0.47	-0.93	-9.15	-4.89	0.07	0.01
Change in Accounts Receivable	0.04	0.07	-0.14	-0.06	0.01	0.02
Change in Inventory	-	-	-	0.02	5.85	0.14
Change in Accounts Payable	2.13	-1.29	4.47	2.39	1.83	-1.5
Change in Other Net Operating Assets	0.53	0.68	1.42	-2.27	0.64	-0.28
Operating Cash Flow	-22.16	-25.18	-27.22	-23.54	-9.13	-11.38
Capital Expenditures	-0.02	-0.06	-0.07	-0.01	-0.04	-0.42
Investing Cash Flow	-0.02	-0.06	-0.07	-0.01	-0.04	-0.42
Long-Term Debt Repaid	-	-0.06	-0.05	-0.05	-0.05	-0.02
Total Debt Repaid	-0.06	-	-	-	-	-
Net Debt Issued (Repaid)	-0.06	-0.06	-0.05	-0.05	-0.05	-0.02
Issuance of Common Stock	0.09	-	-	98.72	17.43	2.05
Other Financing Activities	-	-	-	-5.23	-1.09	-
Financing Cash Flow	0.03	-0.06	-0.05	93.44	16.3	2.03
Foreign Exchange Rate Adjustments	1.25	0.76	2.92	-0.01	-0.06	-
Net Cash Flow	-20.89	-24.54	-24.43	69.87	7.07	-9.78
Free Cash Flow	-22.18	-25.24	-27.3	-23.55	-9.17	-11.8
Free Cash Flow Margin	-	-	-	-29904.22%	-	-
Free Cash Flow Per Share	-0.34	-0.39	-0.44	-0.54	-0.31	-0.46
Levered Free Cash Flow	-9.74	-14.99	-20.64	-4.61	-1.61	-6.06
Unlevered Free Cash Flow	-9.74	-14.99	-20.64	-4.61	-1.61	-6.06
Change in Net Working Capital	-4.41	0.73	0.49	-6.74	-8.32	1.62

Source: S&P Capital IQ. Standard template.